{"symbol":"ABT","fiscalQuarter":"Q2-2026","reportDate":"2026-07-16","reportTime":"BMO","status":"upcoming","company":{"name":"Abbott Laboratories","sector":"Health Care","industry":"Health Care Equipment"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/ABT/earnings/Q2-2026","estimates":{"consensusEps":1.2772,"consensusRevenue":12536.09,"epsLow":1.26,"epsHigh":1.29,"whisperEps":null,"numAnalysts":null},"preBrief":{"companySnapshot":"Abbott Laboratories (ABT) is a global health care company that develops and manufactures a wide range of medical devices, diagnostics, and nutritional products. With a market cap of $160 billion, Abbott plays a crucial role in the health care sector, focusing on innovation and improving patient outcomes.","keyMetrics":[{"name":"Earnings Per Share (EPS)","why":"EPS is a key indicator of profitability and helps investors gauge the company's financial health.","consensus":"$1.28"},{"name":"Revenue","why":"Revenue growth reflects the company's ability to sell its products and expand its market share.","consensus":"$12.5B"}],"lastQuarterRecap":{"summary":"In Q1-2026, Abbott reported an EPS of $1.15, slightly beating estimates. However, the stock fell 6% the following day, indicating market skepticism despite the positive surprise.","promises":[]},"wallStreetExpectations":{"summary":"Analysts expect Abbott to report strong earnings, with a consensus EPS of $1.28 and revenue of $12.5 billion. The market is closely watching for any signs of growth in key product segments.","bullCase":"If Abbott exceeds EPS and revenue expectations, it could signal robust demand for its products, leading to a positive stock reaction.","bearCase":"Conversely, if Abbott fails to meet expectations or provides weak guidance, it may raise concerns about its growth prospects, resulting in a negative market reaction."},"optionsSignal":{"impliedMove":"8.67%","context":"The options market is pricing in a significant move around the earnings report, suggesting heightened volatility expectations.","historicalAvgMove":"4.6%","richness":"rich","richnessContext":"Options are pricing an 8.67% move, while the stock has historically averaged only a 4.6% move, indicating a rich setup."},"earningsTrackRecord":[{"quarter":"Q1-2026","epsSurprise":"+0.61%","reaction":"-6.00%"},{"quarter":"Q4-2025","epsSurprise":"+0.20%","reaction":"-10.04%"},{"quarter":"Q3-2025","epsSurprise":"+0.15%","reaction":"-2.87%"},{"quarter":"Q2-2025","epsSurprise":"+0.80%","reaction":"-8.52%"},{"quarter":"Q1-2025","epsSurprise":"+1.96%","reaction":"+2.76%"}],"pivotalQuestions":[{"question":"Will Abbott's revenue growth meet or exceed the consensus estimate of $12.5 billion?","whyItMatters":"Revenue performance is critical for assessing the company's market position and growth trajectory, especially in a competitive health care landscape."},{"question":"What insights will management provide regarding product demand and market trends?","whyItMatters":"Management's commentary on product demand can significantly influence investor sentiment and expectations for future performance."}],"thesisBreakLevels":{"bullTrigger":"An EPS of $1.30 or higher, coupled with revenue exceeding $12.7 billion, would confirm a strong bull case.","bearTrigger":"An EPS below $1.26 or revenue falling short of $12.3 billion would confirm a bearish outlook.","context":"The market is debating Abbott's ability to sustain growth amid competitive pressures and changing health care dynamics."},"scenarioPlaybook":{"beatAndRaise":"If Abbott beats expectations, history suggests a potential average move of +2.89% on the day, confirming strong demand.","inLineCautious":"If results are in line with expectations, the stock may react cautiously, reflecting ongoing market uncertainty.","miss":"A miss could lead to a decline in stock price, with historical patterns suggesting an average drop of around -3.34%."},"peerReadThroughs":[],"setupPatternInsight":{"pattern":"Prior-quarter beat + options rich in Health Care","sampleSize":30,"fadeRate":"13 of 29 (45%)","insight":"This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held \u2014 no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias)."},"whatTheStreetIsMissing":{"thesis":"The Street may be underestimating Abbott's ability to outperform due to strong underlying demand for its products, particularly in diagnostics and nutrition.","supportingPoints":["Options pricing indicates a potential move of 8.67%, suggesting the market anticipates significant volatility.","Abbott's historical EPS beat rate of 100% over the last quarters indicates a consistent ability to exceed expectations."],"riskToConsensus":"If revenue growth is significantly below the expected $12.5 billion, it could challenge the positive sentiment surrounding Abbott's growth prospects."},"whatToListenFor":["Updates on demand trends for key product lines, especially diagnostics and nutrition.","Any changes to guidance or outlook for the remainder of the fiscal year.","Insights into competitive pressures in the health care equipment sector.","Management's perspective on market opportunities and challenges.","Details on cost management and efficiency initiatives."],"metaDescription":"Abbott Laboratories (ABT) reports Q2 2026 earnings July 16. Analysts expect $1.28 EPS on $12.5B revenue. Here's what to watch."}}